You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Colorcon
Merck
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 7,560,436

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,560,436
Title:Methods of treating gastrointestinal inflammation
Abstract: The present invention provides methods of treating gastrointestinal inflammation, methods of treating inflammatory bowel disease, methods of treating Crohn\'s Disease, and methods of treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and/or that activates a Type I interferon signaling pathway in the individual.
Inventor(s): Raz; Eyal (Del Mar, CA), Katakura; Kyoko (San Diego, CA), Lee; Jongdae (San Diego, CA), Rachmilewitz; Daniel (Tel Aviv, IL)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:11/359,945
Patent Claims:see list of patent claims

Details for Patent 7,560,436

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial The Regents of the University of California (Oakland, CA) 2025-02-22 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial The Regents of the University of California (Oakland, CA) 2025-02-22 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial The Regents of the University of California (Oakland, CA) 2025-02-22 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial The Regents of the University of California (Oakland, CA) 2025-02-22 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial The Regents of the University of California (Oakland, CA) 2025-02-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Medtronic
Moodys
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.